Quality of INR control and outcomes following venous thromboembolism

Clinical and Applied Thrombosis/Hemostasis

Volumn 18, Issue 4, 2012, Pages 370-378

  Gallagher, Arlene M ^a,b   De Vries, Frank ^b   Plumb, Jonathan M ^c   Haß, Bastian ^c   Clemens, Andreas ^c   Van Staa, Tjeerd Pieter ^a,b  

^a MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY   (United Kingdom)

^b UTRECHT UNIVERSITY   (Netherlands)

^c BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

coumarins; international normalized ratio; thromboembolism; VTE

Indexed keywords

ACENOCOUMAROL; ANTICOAGULANT AGENT; COUMARIN DERIVATIVE; PHENINDIONE; WARFARIN;

ADULT; AGED; ANTICOAGULATION; ARTICLE; CASE CONTROL STUDY; CLINICAL PRACTICE; CONTROLLED STUDY; FEMALE; HUMAN; INTERNATIONAL NORMALIZED RATIO; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RECURRENCE RISK; RISK; VENOUS THROMBOEMBOLISM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; DATABASES, FACTUAL; FEMALE; GREAT BRITAIN; HUMANS; INCIDENCE; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; RISK FACTORS; THROMBOEMBOLISM;

EID: 84863459468     PISSN: 10760296     EISSN: 19382723     Source Type: Journal    
DOI: 10.1177/1076029611426139     Document Type: Article

References (19)

1. Kyle PA, Eichringer S. Deep venous thrombosis. Lancet. 2005; 365(9465):1163-1174.
2. Samama MM. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. Arch Intern Med. 2000;160(22):3415-3420.
3. Büller HR, Agnelli G, Hull RD, Hyers TM, Prins MH, Raskob GE. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 suppl):401S-428S. (Pubitemid 39297960)
4. Lawrenson R, Todd JC, Leydon GM, Williams TJ, Farmer RD. Validation of the diagnosis of venous thromboembolism in general practice database studies. Br J Clin Pharmacol. 2000;49(6): 591-596. (Pubitemid 30326559)
5. Huerta C, Johansson S, Wallander MA, García Rodríguez LA. Risk factors and short-term mortality of venous thromboembolism diagnosed in the primary care setting in the United Kingdom. Arch Intern Med. 2007;167(9):935-943. (Pubitemid 46762756)
6. Rosendaal FR, Cannegieter SC, van der Meer FJ, Briët E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993;69(3):236-239. (Pubitemid 23069000)
7. Ramlau-Hansen H. Smoothing counting process intensities by means of kernel functional. Ann Statist. 1983;11:453-466.
8. Eichinger S, Hron G, Bialonczyk C, et al. Overweight, obesity, and the risk of recurrent venous thromboembolism. Arch Intern Med. 2008;168:1678-1683.
9. Heit JA, Mohr DN, Silverstein MD, Petterson TM, O'Fallon WM, Melton LJ 3rd. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med. 2000;160:761-768. (Pubitemid 30165236)
10. Cushman M, Tsai AW, White RH, et al. Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology. Am J Med. 2004;117(1): 19-25. (Pubitemid 38801482)
11. McRae S, Tran H, Schulman S, Ginsberg J, Kearon C. Effect of patient's sex on risk of recurrent venous thromboembolism: a meta-analysis. Lancet. 2006;368(9533):371-378. (Pubitemid 44108120)
12. Willey VJ, Bullano MF, Hauch O, et al. Management patterns and outcomes of patients with venous thromboembolism in the usual community practice setting. Clin Ther. 2004;26(7):1149-1159. (Pubitemid 39141818)
13. Spencer FA, Gore JM, Lessard D, Douketis JD, Emery C, Goldberg RJ. Patient outcomes after deep vein thrombosis and pulmonary embolism: the Worcester Venous Thromboembolism Study. Arch Intern Med. 2008;168(4):425-430. (Pubitemid 351347134)
14. Harrison L, McGinnis J, Crowther M, Ginsberg J, Hirsh J. Assessment of outpatient treatment of deep-vein thrombosis with low-molecular-weight heparin. Arch Intern Med. 1998; 158(18):2001-2003. (Pubitemid 28465624)
15. Tillman DJ, Charland SL, Witt DM. Effectiveness and economic impact associated with a program for outpatient management of acute deep vein thrombosis in a group model health maintenance organization. Arch Intern Med. 2000;160(19): 2926-2932. (Pubitemid 32009049)
16. Schulman S, Kearon C, Kakkar AK, et al RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361(24):2342-2352.
17. Morgan CL, McEwan P, Tukiendorf A, Robinson PA, Clemens A, Plumb JM. Warfarin treatment in patients with atrial fibrillation: observing outcomes associated with varying levels of INR control. Thromb Res. 2009;124(1):37-41.
18. Kimmel SE, Chen Z, Price M, et al. The influence of patient adherence on anticoagulation control with warfarin: results from the International Normalized Ratio Adherence and Genetics (IN-RANGE) Study. Arch Intern Med. 2007;167(3): 229-235.
19. Sington JD, Cottrell BJ. Analysis of the sensitivity of death certificates in 440 hospital deaths: a comparison with necropsy findings. J Clin Pathol. 2002;55(7):499-502. (Pubitemid 34779300)